Latest Health News

Elsight reported a robust 32% increase in annual revenue for 2024, driven by a strategic pivot towards the defense sector, which now accounts for over half of its total revenue. The company’s expanding customer base and debt elimination position it well for growth in 2025.

Bindi Metals reports a significant 3.3 km by 0.6 km antimony soil anomaly at its Kreva prospect in Serbia, alongside steady progress on the Lisa Project application and a solid cash position of $1.866 million.

Omnia Metals Group has identified promising gold, copper, nickel, and PGE anomalies at its Ord Basin Project, setting the stage for expanded exploration in 2025. The company also advances its Salt Creek Project with a Heritage Survey planned, while maintaining strong ESG and safety standards.

Triton Minerals has secured A$17 million from the sale of a 70% stake in its Mozambique graphite assets, while progressing environmental approvals and unveiling promising high-grade gold and copper results at its new Aucu project.

Wellnex Life Limited reported a 36% rise in Q2 FY25 cash receipts and record monthly sales, while advancing its dual listing on the London Stock Exchange and expanding into the UK market.

GBM Resources reports robust progress in its Queensland and South Australian gold projects, highlighted by a $12 million farm-in deal at Twin Hills and positive cash flow from White Dam. Exploration strategies and corporate restructuring set the stage for a pivotal 2025.

Voltaic Strategic Resources reports significant gold and poly-metallic mineralisation at its Kooline and Meekatharra projects, alongside a strategic board restructure and a robust cash position of $5.4 million.

RooLife Group Ltd (ASX:RLG) reports a remarkable 144% jump in Q2 FY25 sales revenue, driven by new online stores and strategic market entries into China and India. The company’s own branded health and wellness products are central to its growth strategy.

Emyria Limited reports strong progress in its MDMA and psilocybin-assisted therapy programs alongside a successful $2.525 million capital raise, positioning the company for expanded mental health treatment services.

Anagenics Limited reports a marked reduction in cash outflows and operating costs following a strategic restructuring, with full benefits expected in the latter half of FY2025. Despite divesting Face Medi, core cosmetics sales remain steady.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.

Tribune Resources Limited has announced an on-market buy-back of up to 5.25 million shares, signaling confidence in its capital structure and aiming to enhance shareholder value over the next year.